
Opus Genetics (IRD) Stock Forecast & Price Target
Opus Genetics (IRD) Analyst Ratings
Bulls say
Opus Genetics is a clinical-stage ophthalmic biotech company with a strong pipeline of AAV-based therapies targeting rare retinal diseases. With successful funding and a strong leadership team in ophthalmology, the company's lead candidate has shown promising results for treating inherited retinal diseases. However, potential challenges may arise in marketing and competition due to Viatris acquiring the rights to an effective eye dilation treatment discovered by Dr. Bennett, and there are also potential risks to Opus' patents and intellectual property.
Bears say
Opus Genetics is a clinical-stage biopharmaceutical company with a focus on developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. However, the limited clinical dataset across its lead IRD programs, lack of prior commercial launch experience, and ongoing net loss in financials indicate fundamental risks for the company. Furthermore, although Opus has a robust preclinical pipeline and potential expansion opportunities, the success of its two lead gene therapy programs remains crucial for achieving its target price. Overall, these risks and uncertainties lead to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.
Opus Genetics (IRD) Analyst Forecast & Price Prediction
Start investing in Opus Genetics (IRD)
Order type
Buy in
Order amount
Est. shares
0 shares